Effects of neoadjuvant glucagon-like-peptide 1 receptor agonists on weight loss after bariatric surgery
Surgery for Obesity and Related Diseases · 2026
DOI: 10.1016/j.soard.2025.09.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Surgery for Obesity and Related Diseases, 2026. Verfasst von Maria Charina Benavidez und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Minimally Invasive and Bariatric Surgery, Department of Surgery, Rush University Medical Center, Chicago, Illinois. Hauptthemen laut MEDLINE: Weight Loss, Glucagon-Like Peptide-1 Receptor Agonists, Obesity, Morbid, Bariatric Surgery. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly prevalent medications used to treat patients with obesity. While bariatric surgery remains the most successful single intervention, many surgical patients have been on a GLP-1RA. OBJECTIVES: This study aims to determine if the neoadjuvant use of GLP-1RA affects surgical weight loss. SETTING: University Hospital, United States. METHODS: This retrospective cohort study compared outcomes of patients undergoing sleeve gastrectomy (SG) or Roux-en-Y gastric bypass (RYGB) who were treated preoperatively with and without GLP-1RAs from July 2022 to June 2023. T-tests and multivariable analyses were utilized to determine significant differences in weight loss. RESULTS: Of 422 patients, 36 (8.5%) received neoadjuvant GLP-1RAs and 386 (91.5%) did not. Mean preoperative body mass index (BMI) was 47 for both groups. Median time for GLP1-RAs was 12 months prior to bariatric surgery but not resumed after. There was a significant difference between patients who received neoadjuvant GLP1-RAs versus those who did not at 2 weeks (mean change in BMI of -4.9 vs -3.8, P = .006), but not at 3- (-9 vs -8.4, P = .25), 6- (-12.4 vs -11.2, P = .13), or 12 months (-14.2 [n = 21] vs -12.9 [n = 249], P = .25) postoperatively. Multivariable analysis showed no difference in weight loss at any time point when adjusting for operation type. CONCLUSIONS: Although neoadjuvant GLP-1RAs did not significantly impact weight loss after bariatric surgery, there was an additive weight loss effect.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Minimally Invasive and Bariatric Surgery, Department of Surgery, Rush University Medical Center, Chicago, Illinois.
- Division of Minimally Invasive and Bariatric Surgery, Department of Surgery, Rush University Medical Center, Chicago, Illinois. Electronic address: Nicholas_j_skertich@rush.edu.
Zitieren
APA
Benavidez, M. C., Redpath, S., Trautmann, S., Ceron, S., Schimpke, S., Myers, J., Omotosho, P., Torquati, A., & Skertich, N. J. (2026). Effects of neoadjuvant glucagon-like-peptide 1 receptor agonists on weight loss after bariatric surgery. Surgery for Obesity and Related Diseases. https://doi.org/10.1016/j.soard.2025.09.010
Vancouver
Benavidez MC, Redpath S, Trautmann S, Ceron S, Schimpke S, Myers J, et al. Effects of neoadjuvant glucagon-like-peptide 1 receptor agonists on weight loss after bariatric surgery. Surgery for Obesity and Related Diseases. 2026. doi:10.1016/j.soard.2025.09.010
BibTeX
@article{Benavidez2026,
author = {Benavidez, Maria Charina and Redpath, Sophia and Trautmann, Stephanie and Ceron, Santiago and Schimpke, Scott and Myers, Jonathan and Omotosho, Philip and Torquati, Alfonso and Skertich, Nicholas J},
title = {Effects of neoadjuvant glucagon-like-peptide 1 receptor agonists on weight loss after bariatric surgery},
journal = {Surgery for Obesity and Related Diseases},
year = {2026},
doi = {10.1016/j.soard.2025.09.010}
}
EUVIMED